Keywords: Vivalis, EB66, MAbs production, Vaccines

Vivalis signs another EB66 out-licensing deal for MAb production

Article | 14 March 2012

Print This

French biotech firm Vivalis (NYSE Euronext: VLS) has signed a joint collaboration and commercial license agreement related to the use ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in